Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 201–300 of 670
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 20
Azamor, T., Horbach, I. S., Cunha, D. B. E., Melgaço, J. G., da Silva, A. M. V., Tubarão, L. N., Azevedo, A. D. S., Santos, R. T., Alves, N. D. S., Machado, T. L., et al. (2022) · Viruses · doi:10.3390/v14091916 · Cited by 14
“Regarding ChAadOx1 nCoV-19 vaccine safety, clinical trials showed rare serious adverse reactions and self-limiting adverse events [26].”
BackgroundJonny, J., Putranto, T. A., Yana, M. L., Sitepu, E. C., Irfon, R., Ramadhani, B. P., Sofro, M. A. U., Nency, Y. M., Lestari, E. S., Triwardhani, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122389 · Cited by 12
Gordeychuk, I. V., Kozlovskaya, L. I., Siniugina, A. A., Владимировна, Я. Н., Kuzubov, V. I., Анатольевич, З. К., Volok, V. P., Dodina, M., Gmyl, L. V., Коротина, Н. А., et al. (2023) · Viruses · doi:10.3390/v15091828 · Cited by 14
SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion
Ruan, W., Gao, P., Qu, X., Jiang, J., Zhao, Z., Qiao, S., Zhang, H., Yang, T., Li, D., Du, P., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105634 · Cited by 14
“S and Gam-COVID-Vac (Sputnik V) 17 – 19 ; and the protein subunit vaccine NVX-CoV2373, 20 were designed based on the SARS-CoV-2 full-length S protein.”
Fever following Covid‐19 vaccination in subjects with Brugada syndrome: Incidence and management
Santoro, F., Crea, P., Pellegrino, P. L., Cetera, R., Gianfrancesco, D., Abumayyaleh, M., Dattilo, G., Allegra, M., Mancini, N., D’Arienzo, G., et al. (2022) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15596 · Cited by 12
van Ewijk, C. E., Kooijman, M. N., Fanoy, E. B., Raven, S. F. H., Middeldorp, M., Shah, A. A., de Gier, B., de Melker, H. E., Hahné, S. J. M., & Knol, M. J. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.45.2200217 · Cited by 14
Kulkarni, P. S., Kadam, A., Godbole, S., Bhatt, V. R., Raut, A. V., Kohli, S., Tripathi, S. K., Kulkarni, P., Ludam, R., Prabhu, M., et al. (2023) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100139 · Cited by 13
Lin, Y.-H., Huang, H., & Hwang, W.-Z. (2022) · Medicine · doi:10.1097/md.0000000000028756 · Cited by 13
“In contrast to the ChAdOx1 nCoV-19 vaccine, adverse reactions after the second dose were reported milder and less frequent.([5]) Thus, vaccination providers and recipients need to expect that there may be some side effects after either dose of different vaccines.”
ResultRoadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Shapiro, J. R., Morgan, R., Leng, S. X., & Klein, S. L. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.836642 · Cited by 13
“The COVID-19 vaccine clinical trials revealed remarkably high efficacy against the ancestral virus at all ages but did not provide estimates disaggregated by sex within each age group (Baden et al., 2020; Polack et al., 2020; Falsey et al., 2021; Sadoff et al., 2021).”
BackgroundAgallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 13
Cargill, T. N., Cicconi, P., Brown, A., Holland, L., Karanth, B., Rutkowski, K. T., Ashwin, E., Mehta, R., Chinnakannan, S. K., Sebastian, S., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100885 · Cited by 13
Seguridad de las vacunas contra la COVID-19
Chaparro-Mérida, N. A., Samper, D. M., & Lacato, A. O. F. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9308 · Cited by 25
A review on COVID-19 transmission, epidemiological features, prevention and vaccination
Zhang, Y., Wu, G., Chen, S., Xu, J., Yimaer, W., Zhang, W., Lin, S. C. C., Hao, Y., Gu, J., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2021-0023 · Cited by 15
Goldman, J. D., Gonzalez, M. A., Rüthrich, M. M., Sharon, E., & von Lilienfeld‐Toal, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359656 · Cited by 14
Pařenica, J., Benešová, K., Radvan, M., Sanca, O., Hlásenský, J., Lokaj, P., Ondrúš, T., Helánová, K., Kala, P., Dušek, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.998842 · Cited by 12
Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults
Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.11.002 · Cited by 15
“5) observed for all age groups.(64) A homologous booster dose of ChAdOx1 nCoV-19 given 6 to 8 months after completion of the primary series produced similar levels of boosting effect on anti-spike IgG and cellular responses after 28 days between older adults aged 70 years or older and adults aged between 18 and 69 yea…”
Wang, Q., Ning, J., Chen, Y., Li, B., Shi, L., He, T., Zhang, F., Chen, X., Zhai, A., & Wu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008420 · Cited by 15
“, 2021), viral vector vaccines (Falsey et al., 2021; Halperin et al., 2022), and inactivated viral vaccines (Wang et al.”
BackgroundPetro-Turnquist, E. M., Pekarek, M. J., Jeanjaquet, N. E., Wooledge, C., Steffen, D. J., Vu, H. L. X., & Weaver, E. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1143451 · Cited by 12
Stebbings, R., Jones, C., Cotton, P., Armour, G., Maguire, S., Skellett, V., Tang, C.-M., Goodman, J., Brady, T. M., Takahashi, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836492 · Cited by 12
“Collectively these findings, alongside data from pivotal Phase 3 studies (7, 47) and ongoing pharmacosurveillance, support the continued use of AZD1222 to mitigate the COVID-19 pandemic.”
ResultBenn, C. S., Schaltz‐Buchholzer, F., Nielsen, S., Netea, M. G., & Aaby, P. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4072489 · Cited by 12
A systematic review of current status and challenges of vaccinating children against SARS-CoV-2
Zhang, M., Zhang, P., Liang, Y., Du, B., Li, L., Yu, Z., Wang, H., Wang, Q., Zhang, X., & Zhang, W. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.006 · Cited by 11
Xing, M., Wang, Y., Wang, X., Liu, J., Dai, W., Hu, G., He, F., Zhao, Q., Li, Y., Sun, L., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00724-23 · Cited by 12
“S (Johnson & Johnson), Sputnik V (Gamaleya Research Institute), and Ad5-nCoV (CanSino Biologics) (10–12).”
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2
Murala, M. S. T., Gairola, V., Sayedahmed, E. E., & Mittal, S. K. (2025) · Vaccines · doi:10.3390/vaccines13040406 · Cited by 12
“The vaccine efficacy for preventing SARS-CoV-2 infection was 64.3% [80].”
InfluentialRzymski, P., Sikora, D., Zeyland, J., Poniedziałek, B., Kiedik, D., Falfushynska, H., & Fal, A. (2022) · Vaccines · doi:10.3390/vaccines10050754 · Cited by 12
The design and analysis of vaccine trials for COVID ‐19 for the purpose of estimating efficacy
Senn, S. J. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2226 · Cited by 12
Solís-Andrade, K. I., González‐Ortega, O., Govea‐Alonso, D. O., Comas‐García, M., & Rosales‐Mendoza, S. (2022) · Vaccines · doi:10.3390/vaccines10101759 · Cited by 10
Waisner, H., Grieshaber, B., Saud, R., Henke, W., Stephens, E., & Kalamvoki, M. (2022) · bioRxiv · doi:10.1128/spectrum.03707-22 · Cited by 8
“Several highly effective vaccines have received use authorization, but the slow global vaccination rate and accumulation of adaptive mutations in different proteins of the virus, particularly the Spike protein, yield novel variants with different immunoevasion properties (2-5).”
BackgroundPai, M., Tung, K., Hsu, S., Peng, Y., Lin, W., Yang, J., Wu, H., Chiu, Y., Shu, K.-H., & Tsai, W. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2172432 · Cited by 9
Baek, Y. J., Kim, W., Ko, J., Lee, Y.-J., Ahn, J. Y., Kim, J. H., Jang, H. C., Jeong, H. W., Kim, Y. C., Park, Y. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.063 · Cited by 12
“Two doses of BNT162b2 had 95 % (95 % confidence interval [CI], 90– 98 %) efficacy against symptomatic COVID-19 [2], and two doses of AZD1222 had 70 % (95 % CI, 55–81 %) efficacy [3].”
BackgroundSager, J. E., El‐Zailik, A., Passarell, J. A., Roepcke, S., Li, X., Aldinger, M., Nader, A., Skingsley, A., Alexander, E. L., Yeh, W. W., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12958 · Cited by 12
“administration, (2) identify and quantify the effects of intrinsic and extrinsic factors influencing the pharmacokinetics (PK) of sotrovimab using systematic covariate analysis, (3) describe the relationship between sotrovimab exposure and probability of progression of COVID19 based on i.”
MethodPriority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply
Galli, M., Zardini, A., Gamshie, W. N., Santini, S., Tsegaye, A., Trentini, F., Marziano, V., Guzzetta, G., Manica, M., d’Andrea, V., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32501-y · Cited by 11
“In the model, vaccinated individuals are assumed to receive two doses of vaccine which significantly reduce their risk of infection and of developing severe outcomes [28-34].”
BackgroundGraham, S., Tessier, E., Stowe, J., Bernal, J. L., Parker, E. P. K., Nitsch, D., Miller, E., Andrews, N. J., Walker, J. L., & McDonald, H. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39674-0 · Cited by 12
O’Neill, A., Mantri, C. K., Tan, C. W., Saron, W. A. A., Nagaraj, S. K., Kala, M. P., Joy, C. M., Rathore, A. P. S., Tripathi, S., Wang, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104924 · Cited by 12
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 16
“Less than half of the studies reported the plan for monitoring and rules for stopping the trial because of harms (31%), the withdrawal person on each harm (49%), and definition use for AEs analysis set (41%).”
BackgroundInfluentialSripongpun, P., Pinpathomrat, N., Bruminhent, J., & Kaewdech, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.924454 · Cited by 11
“6% of patients with liver diseases enrolled in a subsequent study (78).”
BackgroundLiozon, É., Filloux, M., Parreau, S., Gondran, G., Bézanahary, H., Ly, K. H., & Fauchais, A. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247484 · Cited by 10
Chew, C. K., Wang, R., Bavanandan, S., Zainudin, N., Zhao, X., Ahmed, S., Nair, D., Hou, L., Yahya, R., Ch’ng, S. S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01003-x · Cited by 13
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11
“1) for participants 65 years of age or older [50].”
BackgroundNonhuman primate models for evaluation of SARS-CoV-2 vaccines
Neil, J. A., Griffith, M., Godfrey, D. I., Purcell, D. F. J., Deliyannis, G., Jackson, D. C., Rockman, S., Subbarao, K., & Nolan, T. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2071264 · Cited by 12
“More recently, a phase III study in the United States, Chile, and Peru showed a slightly higher vaccine efficacy of 74% [70].”
BackgroundTeeyapun, N., Luangdilok, S., Pakvisal, N., Sainamthip, P., Mingmalairak, S., Poovorawan, N., Sitthideatphaiboon, P., Parinyanitikul, N., Sriuranpong, V., Namkanisorn, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101608 · Cited by 11
Laffan, M., Rees, S., Yadavalli, M., Ferstenberg, L. B., Shankar, N. K., Medin, J., Foskett, N., Arnold, M., da Silva, H. G., Bhuyan, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.007 · Cited by 10
Hitchon, C. A., Mesa, C., Bernstein, C. N., Marrie, R. A., Card, C. M., O’Brien, S. F., & Kim, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071397 · Cited by 13
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina, N. L., Sperotto, M. G., Puga, M. A. M., da Silva, P. V., de Oliveira, R. D., Moore, C. L., Pittet, L. F., Jamieson, T., Dalcolmo, M. P., dos Santos, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172851 · Cited by 12
“Randomised control trials (RCTs) of ChAdOx1-S have reported an overall protective efficacy of 81% (25) against symptomatic COVID-19, with lower protection associated with COVID-19 caused by the variant of concerns (26, 27) Previous studies”
BackgroundMeeraus, W. H., Joy, M., Ouwens, M., Taylor, K., Venkatesan, S., Dennis, J., Tran, T. N., Dashtban, A., Fan, X., Williams, R., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106129 · Cited by 12
“18 Of note, 68% of AZD1222-vaccinated individuals in RAVEN were ≥50 years of age and many had a high comorbidity score (i.e., in CMMS quartiles 3 and 4).”
BackgroundSafety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis
Gil‐Díaz, A., Gil-Hernández, A., Lozano-Jiménez, A. I., Benítez-Peña, J., & Martel, A. C. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.004 · Cited by 10
Guzmán‐López, S., Darwich-Salazar, A., Bocanegra‐Ibarias, P., Treviño, D. S., Flores-Treviño, S., Pérez-Alba, E., Nuzzolo-Shihadeh, L., Pérez‐Rodríguez, E., & Camacho-Ortíz, A. (2022) · Vaccines · doi:10.3390/vaccines10050656 · Cited by 10
“This may be one of the causes why breakthrough infection reports are higher in the reported literature than they were in our study (5% for Pfizer/BioNTech and 26% for AstraZeneca/Oxford) [25,26].”
ResultInfluentialSerum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
Cohen, T. S., Kelly, E. J., Nylander, S., Bansal, H., Jepson, B. M., Bhuyan, P. K., Sobieszczyk, M. E., & Falsey, A. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-11623-9 · Cited by 10
Self-citationYu, Q., Jiang, W., Chen, N., Li, J., Wang, X., Li, M., Wang, D., & Jiang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875637 · Cited by 10
SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination
Vespa, S., Simeone, P., Catitti, G., Buca, D., Bellis, D. D., Pierdomenico, L., Pieragostino, D., Cicalini, I., Boccio, P. D., Natale, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168982 · Cited by 10
“S and Oxford/AstraZeneca ChAdOx1-S).”
Naorungroj, T., Viarasilpa, T., Tongyoo, S., Detkaew, A., Pinpak, T., Wimolwattanaphan, R., Ratanarat, R., Promsin, P., Thamrongpiroj, P., Phumpichet, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1061955 · Cited by 7
Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury
Akkız, H. (2023) · Viruses · doi:10.3390/v15061287 · Cited by 10
“2% of patients treated with lopinavir/ritonavir [97].”
Fabiani, M., Mateo‐Urdiales, A., Sacco, C., Fotakis, E. A., Battilomo, S., Petrone, D., Manso, M. D., Bella, A., Riccardo, F., Stefanelli, P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.074 · Cited by 10
Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 13
A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital
Park, S. Y., Kim, T. H., Lee, E. J., Loeb, M. B., Jeong, Y. S., Kim, J. H., Oh, S. M., Cheong, S., Park, H., Jo, S., et al. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2022.05.010 · Cited by 9
“9) 0 0 Duration of hospitalization/isolation, days 9 (8-10) 13 (9-19) 9 (6-11) .”
Terpos, E., Liontos, M., Fiste, O., Zagouri, F., Briasoulis, Α., Sklirou, A. D., Markellos, C., Skafida, E., Papatheodoridi, A. M., Andrikopoulou, Α., et al. (2022) · Cancers · doi:10.3390/cancers14112796 · Cited by 9
“Up to March 2022, five vaccines had shown clinical efficacy and were approved by the European Medical Agency (EMA), namely BNT162b2, developed by Pfizer BioNTech [6]; NVX-CoV2373, developed by Novavax [7]; mRNA-1273, developed by Moderna; NIAID [8], AZD1222, developed by the University of Oxford and AstraZeneca [9]; a…”
Reyes, L. L., Portugal, W., Huamán, K., & Obregón, C. (2022) · Anales de la Facultad de Medicina · doi:10.15381/anales.v83i2.21531 · Cited by 21
Postvaccinal GABA‐B receptor antibody encephalitis after ChAdOx1 nCoV‐19 vaccination
Ahn, S., Lee, S., & Chu, K. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51659 · Cited by 9
Wang, G., Zhao, K., Han, J. S., Hu, Z., Zhang, T., Wang, Y., Shi, R., Li, Y., Song, Q., Du, H., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.11.008 · Cited by 9
The coverage of medical injuries in company trial informed consent forms
Healy, D., Roux, A. G., & Dressen, B. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-220043 · Cited by 10
Nevola, R., Criscuolo, L., Beccia, D., Femine, A. D., Ruocco, R., Imbriani, S., Alfano, M., Villani, A., Russo, A., Perillo, P., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i5.800 · Cited by 9
Muangnoicharoen, S., Wiangcharoen, R., Nanthapisal, S., Kamolratanakul, S., Lawpoolsri, S., Jongkaewwattana, A., Thitithanyanont, A., Luvira, V., Chinwangso, P., Thanthamnu, N., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.043 · Cited by 10
Pueyo, P. P., Ruberte, E. G., Ordás, J. G., Blanco, L. M., Pascual-Figal, D. A., Larrañaga-Moreira, J. M., Gómez-Barrado, J. J., Calle, D. G., Bonet, L. A., Salinas, G. L. A., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02225-0 · Cited by 9
Takemoto, Y., Tanimine, N., Yoshinaka, H., Tanaka, Y., Takafuta, T., Sugiyama, A., Tanaka, J., & Ohdan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1217206 · Cited by 10
Ramasamy, M., Kelly, E. J., Seegobin, S., Dargan, P. I., Payne, R., Libri, V., Adam, M., Aley, P. K., Martinez-Alier, N., Church, A., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00177-5 · Cited by 9
Self-citationLiu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.034 · Cited by 13
Iwata, S., Pollard, A. J., Tada, Y., Omoto, S., Shibata, R. Y., Igarashi, K., Hasegawa, T., Ariyasu, M., & Sonoyama, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-57308-3 · Cited by 8
“Headache, fatigue, and myalgia were the most common solicited systemic AEs, while pain at the injection site was the most frequently reported solicited local AE, all in agreement with previous published reports on S-268019-b and ChAdOx1 nCoV-19 16–19 .”
Farhat, M., Al-Ibrahim, R., Almohammedali, A., Aljishi, R., & Alalwan, B. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s379204 · Cited by 9
“For the Pfizer vaccine, local side effects at the injection site were more common than systemic ones.(21) On the contrary, for the Oxford-AstraZeneca vaccine, systemic side effects (eg, fatigue) were more common.”
BackgroundGupta, A., Singh, A. P., Singh, V. K., & Sinha, R. P. (2023) · Viruses · doi:10.3390/v15061234 · Cited by 10
“According to two Phase III trials [43,44], the overall immunization efficacy in those who received two standard doses was estimated to be about 70%.”
MethodHernández‐Ávila, M., Ortíz‐Brizuela, E., Tamayo‐Ortiz, M., Zepeda‐Tello, R., Gutiérrez-Díaz, H., Cordera, D. B. S., Vieyra-Romero, W. I., Real-Ornelas, G. A., Méndez-Aranda, M., & Gómez, A. H. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100612 · Cited by 10
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2023) · Vaccines · doi:10.3390/vaccines11101621 · Cited by 11
Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., Lew, J. M., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.028 · Cited by 9
COVID-19: vaccination, therapeutics and a review of the science and public health
Shah, S. K., Bhandari, K., Shah, A., & Chaurasiya, G. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002374 · Cited by 12
“The two doses of the AstraZeneca vaccine have shown 61.7% effectiveness against the B.1.1.7 (UK) variant, 10.4% against mild to moderate due to B.1.351 ( South Africa) variant, and 77.3% against other variants [78] .”
BackgroundInfluentialAssociation Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Janes, H., Fisher, L. H., Kee, J. J., Parameswaran, L., Goepfert, P., Falsey, A. R., Ludwig, J., Magaret, C. A., Gilbert, P. B., Kublin, J. G., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae400 · Cited by 11
Self-citationO’Reilly, S. R., Byrne, J., Feeney, E. R., Mallon, P. W. G., & Gautier, V. (2024) · Vaccines · doi:10.3390/vaccines12101089 · Cited by 11
Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction
Saha, A., Choudhary, S., Walia, P., Kumar, P., & Tomar, S. (2025) · Virology · doi:10.1016/j.virol.2025.110394 · Cited by 9
Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes
Harris, C., Kapingidza, A. B., San, J. E., Christopher, J., Gavitt, T. D., Rhodes, B., Janowska, K., O’Donnell, C., Lindenberger, J. J., Huang, X. Y., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00465-25 · Cited by 10
Lee, C. M., Lee, E., Park, W. B., Choe, P. G., Song, K., Kim, E. S., & Park, S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e252 · Cited by 8
Koen, A. L., Izu, A., Baillie, V. L., Kwatra, G., Cutland, C., Fairlie, L., Padayachee, S. D., Dheda, K. U. J., Barnabas, S. L., Bhorat, Q. E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.058 · Cited by 8
“5) at preventing symptomatic COVID-19 with predominantly the ancestral virus in the United States, Chile, and Peru (data cut-off: March 5, 2021) [5].”
BackgroundResultSelf-citationProtective effect of vaccination on the risk of cardiovascular disease after SARS-CoV-2 infection
Song, J., Choi, S., Jeong, S., Chang, J. Y., Park, S. J., Oh, Y. H., Kim, J. S., Cho, Y., Byeon, K., Choi, J. Y., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02271-8 · Cited by 11
Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 10
Karl, T., Schuster, A., Stangassinger, L. M., Stiboller, T., Cadamuro, J., & Oostingh, G. J. (2023) · Vaccines · doi:10.3390/vaccines11101615 · Cited by 7
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 10
Klinkhardt, U., Schunk, M., Ervin, J. E., Schindler, C., Sugimoto, D. H., Rankin, B. M., Amann, R., Monti, M., Kutschenko, A., Schumacher, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2410574 · Cited by 9
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
Aviraj, K. S., Wasnik, A., Gupta, L., Ranjan, A., & Suresh, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02856-6 · Cited by 12
Choi, H., Lee, S. M., Lim, S., Shin, K., Kim, T., Kim, W.-J., Yun, M.-S., & Oh, S. H. (2021) · Vaccines · doi:10.3390/vaccines9121473 · Cited by 9
The Impact of COVID-19 and Vaccine on the Human Nervous System
Chen, F., Cao, P., Liu, H., & Cai, D. (2022) · Neuroendocrinology · doi:10.1159/000524234 · Cited by 10
Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review
Wu, C.-T., Chin, S., & Chu, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.856991 · Cited by 8
“Although no myocarditis was reported in either group, two cases with cardiac disorders were reported as medically attended adverse events in the ChAdOx1 group compared to 0 events in the placebo group (13).”
ResultTawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Vanichsetakul, P., Thonginnetra, S., Niemsorn, K., Promsena, P., Tandhansakul, M., Kasemlawan, N., Ruangkijpaisal, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10050807 · Cited by 8
Batac, A. L. R., Merrill, K. A., Askin, N., Golding, M. A., Abrams, E. M., Bégin, P., Ben‐Shoshan, M., Ladouceur, E., Roos, L. E., Protudjer, V., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100079 · Cited by 8
“Two clinical trials of the AstraZeneca vaccine were included in this review.(42,45) Of these, 1 reported a single case of anaphylaxis, but no other allergic reactions.”
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
Pacheco-García, U., & Serafín‐López, J. (2023) · Vaccines · doi:10.3390/vaccines11030655 · Cited by 9
Catch me if you can: viral nucleic acids to host sensors
Jung, Y., Grainger, H., Yang, S., Mondal, S., Lukong, K. E., Conn, K. L., & Wu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1632283 · Cited by 8
Ishikawa, K., Nascimento, M., Asano, M., Hirata, H., Itoh, Y., Kelly, E. J., Matsui, A., Olsson, U., Shoemaker, K., & Green, J. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.015 · Cited by 7
“Additionally, our results are consistent with the established AZD1222 safety profile [6,12], indicating that AZD1222 remains well tolerated.”
ResultSelf-citationBell's Palsy After Vaccination Against Covid‐19: A Systematic Review and Meta‐analysis
Gordon, A. J., Varelas, A. N., & Eytan, D. F. (2023) · Otolaryngology · doi:10.1002/ohn.385 · Cited by 7
Fisher, L. H., Kee, J. J., Liu, A., Espinosa, C. M., Randhawa, A. K., Ludwig, J., Magaret, C. A., Robinson, S. T., Gilbert, P. B., Hyrien, O., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.12835 · Cited by 8
Self-citationClemens, S. A. C., Jepson, B. M., Bhorat, Q. E., Ahmad, A., Akhund, T., Aley, P. K., Bansal, H., Bibi, S., Kelly, E. J., Khan, M., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00078-8 · Cited by 7
Self-citationClegg, L. E., Stepanov, O., Matthews, S., White, T., Seegobin, S., Thomas, S., Tuffy, K. M., Någård, M. B., Esser, M. T., Streicher, K. L., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1517 · Cited by 7
Esen, M., Fischer-Herr, J., Gabor, J. J., Gaile, M., Fleischmann, W. A., Smeenk, G. W., de Moraes, R. A., Bélard, S., Calle, C. L., Woldearegai, T. G., et al. (2024) · Vaccines · doi:10.3390/vaccines12111288 · Cited by 9
“The profile of the reported reactions is comparable to other COVID-19 vaccines such as mRNA [45,46] or viral vector-based vaccines [23,47,48], but seemed to be milder and less frequent at the tested doses.”
Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity
van Ewijk, C. E., Hernández, S. S., Jacobi, R. H. J., Knol, M. J., Hahné, S., Wijmenga‐Monsuur, A. J., Boer, M. C., & van de Garde, M. D. B. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100593 · Cited by 8
Advancing ORFV‐Based Therapeutics to the Clinical Stage
Helmold, M., & Amann, R. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70038 · Cited by 8
“The profile of reported reactions is comparable to other COVID‐19 vaccines such as mRNA vaccines [138, 139] or viral vector‐based vaccines [125, 140, 141], but appeared to be milder and less frequent at the tested doses.”
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.